This paper is in the following e-collection/theme issue:

Non-randomized Protocols and Methods (ehealth) (679) Infectious Diseases (non-STD/STI) (1728) Respiratory Medicine (160) Complementary and Alternative Medicine (96) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (216)

Published on in Vol 14 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/65789, first published .
Clinical Safety of Pudilan Xiaoyan Oral Liquid for the Treatment of Upper Respiratory Tract Infection in the Real World: Protocol for a Prospective, Observational, Registry Study

Clinical Safety of Pudilan Xiaoyan Oral Liquid for the Treatment of Upper Respiratory Tract Infection in the Real World: Protocol for a Prospective, Observational, Registry Study

Clinical Safety of Pudilan Xiaoyan Oral Liquid for the Treatment of Upper Respiratory Tract Infection in the Real World: Protocol for a Prospective, Observational, Registry Study

Authors of this article:

Mengmeng Wang1 Author Orcid Image ;   Lianxin Wang1 Author Orcid Image ;   Fumei Liu1 Author Orcid Image ;   Renbo Chen1 Author Orcid Image ;   Zhifei Wang1 Author Orcid Image ;   Xin Cui1 Author Orcid Image ;   Yuanyuan Li1 Author Orcid Image ;   Yanming Xie1 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Journals

  1. Jiang M, Yang Y, Zhang Y, Zhang P, Zhang Q, Yang T, Zhang G, Zhou J, Chu Z, Li S, Wang Y, Zhang J, Shen S, Song P, Wang J, Tang H. Covalent Targeting GAPDH by Pudilan Formula and Baicalein Suppresses Macrophage Warburg Effect to Alleviate Acute Lung Injury. Phytomedicine 2025:157727 View